Introduction
Friedenstein and his colleagues were the first to characterize mesenchymal stem cells (MSC). 1 MSC can differentiate into several tissues, including bone, cartilage and fat in vitro and in vivo.
1-4 MSC may be important for tissue repair, cartilage defects, ruptured tendons and damaged myocardium. 3, [5] [6] [7] MSC have low immunogenicity and immunomodulatory effects. [8] [9] [10] [11] We used MSC to reverse therapy-resistant acute graft-versushost disease (GVHD) with improvement in survival. 12, 13 Because of dramatic repair of the gastrointestinal tract in some patients and because MSC preferentially home to sites of injury, 12, [14] [15] [16] we extended these studies to include patients with toxic damage in various tissues. Here we report a pilot study using MSC for treatment of hemorrhagic cystitis, pneumomediastinum and perforated colon in patients who have undergone treatment with chemoirradiotherapy and allogeneic hematopoietic stem cell transplantation (ASCT).
Patients
Between September 2004 and July 2006, 10 patients were treated with MSC for toxic tissue damage (Table 1) . Follow-up was 1 October 2006. The study was approved by the Ethics Committee at Huddinge University Hospital. Patients and MSC donors gave written informed consent.
Donors
ASCT donors were HLA-identical siblings in five cases, HLA-A, HLA-B and HLA-DRB1-identical matched unrelated donors (MUD) in four, and an unrelated two HLA-antigen mismatched cord blood donor in one (Table 1) . HLA typing was genomic highresolution DNA-based polymerase chain reaction-sequencespecific primer. 17 
Conditioning
Three patients with acute lymphoblastic leukemia (ALL) received cyclophosphamide (Cy) 120 mg/kg, combined with fractionated total body irradiation (TBI) 12 Gy. A boy with thalassemia major and two patients with acute myeloid leukemia (AML) were treated with busulfan (Bu) 16 mg/kg, followed by Cy 200 and 120 mg/kg, respectively. 18 A patient with prostate cancer and a patient with chronic lymphocytic leukemia (CLL) were treated with reduced intensity conditioning (RIC) consisting of fludarabine (30 mg/m 2 /day) for 5 days, combined with Cy 120 mg/kg. 19 Two patients with lymphoma received fludarabine (30 mg/m 2 /day) for 6 days, combined with Cy 60 mg/kg and TBI 3 Gy/day for two consecutive days. MESNA and forced diuresis, 3 l/m 2 /day, was given together with Cy to prevent hemorrhagic cystitis.
Prophylaxis of graft-versus-host disease
Before SCT, four patients with an unrelated donor were treated with thymoglobulin 6-8 mg/kg (Genzyme, MN, USA). 20 One patient with lymphoma received Campath 30 mg (Schering Nordic, Stockholm, Sweden).
To prevent GVHD, methotrexate (MTX) was combined with cyclosporine (CsA). 18, 19 In a patient receiving a cord blood transplant, MTX was replaced by prednisolone and the patient with thalassemia major received tacrolimus combined with sirolimus. 21 Supportive care has been previously described in detail. 19 
Grading and treatment of hemorrhagic cystitis
Hemorrhagic cystitis was graded from 1 to 5 according to the NCI terminology for adverse events. 22 Grade 1: microscopic Harvesting and expansion of MSC Fifty milliliters of bone marrow (range 20-65) was aspirated from 12 donors, median age 42 (22-66) years. The Swedish Medical Product Agency approved the method. HLA matching of MSC donors and patients is shown in Table 1 . Heparinized bone marrow cells were separated on Redigrad (Amersham Biosciences AB, Uppsala, Sweden) as described previously in detail. 10 A median of 716 Â 10 6 (range: 140-1350) mononuclear cells was collected, washed and resuspended in Dulbecco's modified eagles medium-low glucose (DMEM-LG) (Life Technologies, Gaithersburg, MD, USA), with a selected batch of 10% fetal bovine serum (National Veterinary Institute, Uppsala, Sweden). The cells were plated at 160 000 cells/cm 2 at 371C in 5% CO 2 . When near confluence, the cells were detached by trypsin and EDTA (Invitrogen Corp., Grand Island, NY, USA), passaged and replated at 4000 cells/cm 2 . The cells were harvested at passage 1-3 (Table 1) . MSC were detached, washed in cliniMACS PBS-EDTA buffer (Amcell Myltenyi Biotech GmbH, Gladbach, Germany) and resuspended in NaCl with 10% AB plasma. Flow cytometry was performed using a FACSort and analyzed with Cellquest software (Becton Dickinson). The cells expressed CD105 and CD73, but not CD34, CD45 or CD14. They were positive for HLA class I, but generally not for class II. The MSC suspensions were culture negative for bacteria, mycoplasma and fungi before infusion. In 11 cases, MSC were used from HLA-mismatched unrelated third-party donors. In three cases, HLA-haploidentical-related donors, different from the ASCT donors, were used. In two cases, MSC were cultured from the HLA-identical ASCT sibling donors.
PCR for detection of DNA from MSC donor
Differences in the HLA type between the MSC donors, the patients and the ASCT donors were used to design primers specific for the MSC donors. A nested PCR was used, with a sensitivity of 10 À5 -10 À6 , in serial dilutions. The first PCR was run for 32 cycles in a 50 ml reaction. 23 The PCR product from the first PCR was diluted 100 times, 10 ml of which was used in a second PCR with another primer pair. Apart from a lower annealing temperature, the PCR parameters of the second PCR were the same as those of the first. The outcomes of the DNA preparation from the biopsies determined the amount of DNA used in the PCRFthis varied from 1 to 6 mg.
Results

Patient outcome Patient 1 (UPN1033).
A 22-year-old male with persistent diarrhea and GVHD developed hemorrhagic cystitis. During cystoscopy, his bladder was accidentally perforated. He required repeated surgery. MSC was given on day 81 with no effect on the diarrhea, but hemorrhages decreased (Table 1) . During the subsequent 10 days, he only required two platelet transfusions. The week before MSC infusion, he required 28 units of erythrocyte concentrate, 14 units of fresh frozen plasma and 9 platelet transfusions. On day 93, he started to bleed again. He was given MSC on day 96 with no effect. He died of multiorgan failure on day 104. Autopsy showed hemorrhages in the urinary bladder, but no perforation.
Patient 2 (UPN1048)
. A 48-year-old male with lymphoma developed gross hematuria on day 16, for which he received MSC 0.9 Â 10 6 /kg. The week before the infusion of MSC, he required 20 erythrocyte transfusions, 8 units of fresh frozen plasma and 9 platelet transfusions. The week after MSC infusion, he required 8 erythrocyte transfusions, 5 units of fresh frozen plasma and 7 units of platelets. His hematuria became uncontrolled, nephrostomies were inserted and he required ventilatory assistance. He died of multiorgan failure. Autopsy showed blood in the urinary tract.
Patient 3 (UPN1068).
A 34-year-old female with ALL developed refractory gastrointestinal GVHD, which responded to MSC given on day 32. She was re-admitted with hemorrhagic cystitis and treated with MSC on day 81. She required six erythrocyte transfusions and five units of platelets. Two weeks after MSC infusion, hematuria disappeared and no further transfusions were needed.
Patient 4 (UPN1098).
A 13-year-old boy with thalassemia major developed hematuria on day 14 and required 1-2 units of platelets per day. He received six erythrocyte transfusions over a period of 11 days. He was given MSC on day 24. He only needed two additional erythrocyte units. His hematuria steadily improved and urine became completely clear with no more microscopic hematuria 20 days after MSC infusion. His requirement for platelets decreased, and a last platelet transfusion was given on day 42.
Patient 5 (UPN1118).
A 54-year-old male was admitted owing to gross hematuria and severe pain. He was treated with MSC on day 48. After MSC infusion, the pain dramatically improved. He was given four platelet transfusions. Gross hematuria disappeared the day after MSC infusion. Microscopic hematuria disappeared after 23 days.
Patient 6 (UPN1131).
A 54-year-old female with steroid refractory grade IV acute GVHD and cytomegalovirus colitis was treated with 1.7 Â 10 6 MSC/kg on day 112. The GVHD did not respond. On day 153, she developed gross hematuria. On day 155, she was given 0.7 Â 10 6 MSC/kg from her HLAidentical brother. One day later, she only had traces of blood in her urine. Microscopic hematuria disappeared after 4 days. She died with progressive GVHD on day 189.
Patient 7 (UPN1152).
A 59-year old-male developed gross hematuria on day 11. He required two units of erythrocytes per day for 3 days and daily fresh-frozen plasma for 3 days in addition to three platelet transfusions per week. He received MSC on day 14, and gross hematuria disappeared after 3 days. After MSC infusion, he only required occasional transfusions.
Patient 8 (UPN1007).
A 59-year-old male received 0.7 Â 10 6 MSC/kg on day 251 due to refractory gastrointestinal GVHD, and diarrhea decreased. CT of thorax showed pneumomediastinum on day 283. On this day, he received 2 Â 10 6 MSC/ kg. His stools became normal. A previous subcutaneous Tissue repair using allogeneic mesenchymal stem cells O Ringdén et al emphysema disappeared, a thoracic scan showed no pneumothorax and he was discharged.
Patient 9 (UPN981).
A 21-year-old female with ALL in the second remission had recurrent disease within 3 months after ASCT. She was treated with donor lymphocytes and went back into remission. One year and 3 months after transplant, she was re-admitted owing to pain, high fever and dyspnea. Thoracic scan showed pneumomediastinum and interstitial infiltrates. She was given MSC and pulmonary x-ray showed no pneumomediastinum.
Patient 10 (UPN1082).
A 64-year-old woman developed non-responsive gastrointestinal GVHD. MSC given on day 49 gave a partial response. On day 56, she had abdominal pain and was treated with Imipenem, Metronidazole and total parenteral nutrition (TPN) (Figure 1 ). On day 70, her diverticulitis perforated with resulting abdominal air, peritonitis and abdominal muscular defense. Surgery was discussed, but the patient refused. On day 79, she was given a second MSC dose. She improved dramatically with disappearance of pain and muscular defense. She started to eat the following day and the abdominal air disappeared (Figure 1 ). Two weeks after MSC infusion, she could feed herself normally. Abdominal CT on day 89 showed an abscess in the descending colon. On day 112, she again had peritonitis. Abdominal X-ray showed air in the abdomen. TPN and antibiotics were started again. Six days later, she was given MSC. The abdominal pain disappeared, but she deteriorated. Abdominal CT on day 123 showed no free air in the abdomen. Four months after transplant, she died from disseminated fungal infections. Autopsy showed diverticulosis, no perforation and an abscess in the pouch of Douglas.
Effects by MSC on tissue toxicity
Among the seven patients with hemorrhagic cystitis, patients 1 and 2 had reduced transfusion requirements. Patient 1 had a bladder perforation, which seemed healed at autopsy. In patients 3-7, gross hematuria disappeared at median 3 (range 1-14) days after MSC infusion and microscopic hematuria disappeared after 23 (4-30) days. Patients 1-7 all had BK virus in their urine. Patient 2 also having urinary adenovirus. In patients 8 and 9, their pneumomediastinum disappeared. In patient 10, peritonitis, due to colonic perforation was reversed twice following MSC infusions.
Survival
Three patients are alive 5, 10 and 16 months after ASCT (Table 1) . Four died from infections, two from multiorgan failure and one from leukemic relapse.
MSC donor DNA in the bladder of a patient with hemorrhagic cystitis
Patient 1 received MSC from two different donors. He died 3 weeks after the first infusion and 1 week after the last infusion. At autopsy, HLA-specific DNA from both donors was detected in the urinary bladder, colon and a lymph node (Figure 2 ). The level of MSC donor DNA was estimated to be between 10 À5 and 10
À6
.
Discussion
The therapeutic potential of MSC has been brought into the spotlight in many fields of research. 12, 14, 24 MSC transduced with green fluorescent protein are widely distributed in a range of tissues, following systemic infusion into primates. 25 Radiolabelled MSC injected intravenously into rats gave high radioactivity first in the lungs and later in the liver and spleen. 16 In humans, data are more limited. 9, 21, 26 The MSC progenies are able to acquire different phenotypes, depending on the tissue to which they home. 27 Chapel and his colleagues showed in primates that MSC homed to damaged tissue after irradiation. 15 Thus, it seems logical to use MSC to treat tissue toxicity induced by chemoirradiotherapy. ASCT patients experience toxic effects such as hemorrhagic cystitis, which occurs in 10-30% of the patients. [28] [29] [30] [31] [32] In our unit, the cumulative incidence of hemorrhagic cystitis was 16%, out of which 3% had grades 3-5. 33 It may be caused by Cy and Bu, correlates with acute GVHD and is associated with BK and adenovirus. [28] [29] [30] [31] [32] [33] [34] BK viremia was more common in patients with hemorrhagic cystitis than those without. 35 However, BK virus in urine is detected in 35% of patients without hemorrhagic cystitis. We identified BK virus in the urine of 7/7 of the patients with hemorrhagic cystitis. In the present study, 4/7 of the patients with hemorrhagic cystitis also had GVHD. There is no effective treatment for severe hemorrhagic cystitis, which is Tissue repair using allogeneic mesenchymal stem cells O Ringdén et al associated with a high mortality. [28] [29] [30] [31] [32] 34 In our unit, the mortality in patients who developed grade 3 hemorrhagic cystitis was 55% and for those who developed grade 4, it was 71%. 34 Following MSC infusions in patient 1, transfusion requirements were reduced. The patient died of multiorgan failure. At autopsy, perforation of the bladder could not be detected. MSC may have healed the perforation and MSC donor DNA was detected in the bladder (Figure 2 ). After infusion in humans, it has been very difficult to detect MSC. 9 The finding of donor DNA from both MSC donors in the damaged bladder is therefore intriguing. This inspired us to use MSC in cases of hemorrhagic cystitis. In patient 2, MSC may have reduced the need for transfusions. In the subsequent five patients, treated at lessadvanced stages, hemorrhagic cystitis disappeared after MSC were given. Although some may have recovered spontaneously, this observation encourages prospective randomized studies using MSC for moderate hemorrhagic cystitis. In severe hemorrhagic cystitis, cystectomy was performed at one center as a life-saving procedure. 36 Thus, it is much more simple to treat hemorrhagic cystitis at an early stage with MSC.
After treatment with MSC, pneumomediastinum disappeared in two patients. Pneumomediastinum often recovers spontaneously and the question of whether or not MSC hastens recovery can only be answered in controlled trials. We wanted to draw attention to the use of MSC in healing damaged lung tissue, because animal data show that MSC first home to the lung after intravenous infusion. 16 The last patient with severe GVHD of the gut, treated with high dose of steroids developed peritonitis after perforation of the diverticulosis. After MSC were given, the perforation and peritonitis recovered twice. Surgery was not performed because of severe GVHD, poor condition, and patient refusal. It is possible that MSC homed to the gut resulting in prompt healing in accordance to what we have seen in severe GVHD. 12, 13 More knowledge is required to understand how MSC participate in this healing process. Is this cell-cell contact induced or a bystander phenomenon mediated by soluble factors? This patient succumbed owing to widespread invasive fungal infection, severe immunoincompetence caused by GVHD and its treatment. MSC have been shown to inhibit T-cell responses in vitro, not only against allo-antigens and mitogens, but also against infectious agents. 9,37 Therefore, MSC may have further immunocompromised this patient, even if fungal infection often occurs in patients with severe acute GVHD. 38 Mortality was high in these patients, which was owing to severe complications and immunoincompetence in high-risk ASCT patients. New medical approaches are first attempted in patients with a dismal prognosis.
Our data demonstrate that MSC home to damaged bladder epithelium in humans. This is supported by experimental animal data showing that MSC home to damaged tissue. 15, 16, 25 This study suggests that MSC may be used to heal toxic damage by chemoirradiotherapy. In high-risk patients with colonic perforation, where operation cannot be performed, MSC and broadspectrum antibiotics may be used as an alternative to transversostomy. MSC may also be tried for severe interstitial cystitis.
To conclude, MSC is a novel therapy for severe tissue toxicity that deserves further evaluation.
